Pharmacology/Pharmaceutical Industry
Guidelines: Medication Algorithms for Depressive Disorder
30 Aug, 2017 | 18:01h | UTC
Systematic Review: Deferasirox for managing iron overload in people with thalassaemia
29 Aug, 2017 | 14:56h | UTCDeferasirox for managing iron overload in people with thalassaemia – Cochrane Library (free)
Full review: Deferasirox for managing iron overload in people with thalassaemia – Cochrane Library (link to abstract – $ for full-text)
Iron chelation with oral Deferasirox (instead of injected deferoxamine) may offer an important treatment option for people with thalassaemia and secondary iron overload.
Systematic Review: Benefits and harms of sugammadex versus neostigmine in reversing induced paralysis
29 Aug, 2017 | 14:59h | UTCFull review: Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults – Cochrane Library (link to abstract – $ for full-text)
“sugammadex may work more rapidly than neostigmine to reverse neuromuscular block in adults” (RT @CochraneUK see Tweet)
#ESCCongress – Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation
27 Aug, 2017 | 20:07h | UTCCommentaries: Randomized Evaluation of Dual Antithrombotic Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With Nonvalvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention – RE-DUAL PCI – American College of Cardiology, Latest in Cardiology (free) Dual Antithrombotic Therapy Is Safe for Patients with AF and a New Stent – Physician’s First Watch (free) AND When two is better than three: Dual antithrombotic therapy cuts bleeding risk – Brigham and Women’s Hospital, via ScienceDaily (free)
“In summary, several lines of evidence now suggest that it is safe to treat atrial fibrillation patients who undergo coronary revascularization with anticoagulation (warfarin studied in WOEST, rivaroxaban studied in PIONEER AF-PCI, dabigatran studied in RE-DUAL PCI) and clopidogrel monotherapy” (from American College of Cardiology, Latest in Cardiology).
#ESCCongress – Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
27 Aug, 2017 | 20:06h | UTCEditorial: Targeting Inflammation in Coronary Artery Disease (free)
Commentaries: Anti-Inflammatory Therapy for Atherosclerotic Disease: A Step Closer? – Physician’s First Watch (free) AND CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events – TCTMD (free) AND CANTOS Validates Role Of Inflammation In Heart Disease – Cardiobrief (free)
“This widely anticipated study delivered some modestly positive results (fewer nonfatal MIs), some worrisome results (increased fatal infections), and some unexpected results (fewer cancer deaths)” (from Physician’s First Watch).
#ESCCongress – 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease
27 Aug, 2017 | 20:09h | UTC2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS (free) (RT @rafavidalperez see Tweet)
See also: #ESCCongress Slides (free PPT file)
#ESCCongress – Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
27 Aug, 2017 | 20:08h | UTCEditorial by Dr. Eugene Braunwald: An Important Step for Thrombocardiology (free)
Commentaries: Cardiovascular Outcomes for People Using Anticoagulation Strategies – COMPASS – American College of Cardiology, Latest in Cardiology (free) AND COMPASS: Does Rivaroxaban Plus Aspirin Improve CV Outcomes in Patients With Stable Atherosclerotic Vascular Disease or PAD? – ACC News Story (free) AND Rivaroxaban, Aspirin, or Both in Stable Coronary Disease – Physician’s First Watch (free)
The primary outcome (composite of cardiovascular death, stroke, or myocardial infarction) occurred in fewer patients in the rivaroxaban-plus-aspirin group than in the aspirin-alone group (4.1% vs. 5.4% / Absolute risk difference = 1.3% / NNT = 76), but major bleeding events occurred in more patients in the rivaroxaban-plus-aspirin group (3.1% vs. 1.9% / Absolute risk difference = 1.2 / NNH = 83).
Viewpoint: Management of Parkinson Disease in 2017
26 Aug, 2017 | 20:17h | UTCViewpoint: Management of Parkinson Disease in 2017: Personalized Approaches for Patient-Specific Needs – JAMA (free)
Systematic Review: Low molecular weight heparin for prevention of venous thromboembolism in patients with lower-limb immobilization
26 Aug, 2017 | 19:37h | UTCLow molecular weight heparin for prevention of venous thromboembolism in patients with lower-limb immobilization – Cochrane Library (link to abstract – $ for full-text)
“Moderate-quality evidence showed that the use of LMWH in outpatients reduced DVT when immobilization of the lower limb was required, when compared with no prophylaxis or placebo”.
Study: Gastrointestinal Safety of Direct Oral Anticoagulants
26 Aug, 2017 | 16:46h | UTCCommentary: Which NOACS are riskiest for gastrointestinal bleeding? – Pharmacy News (free)
Source: ACP Journal Club ($)
Observational study suggests Apixaban may be associated with a more favorable gastrointestinal safety profile. Further randomized trials are needed to confirm these findings.
Systematic Review: First- and Second-Generation Antipsychotics in Children and Young Adults
26 Aug, 2017 | 16:04h | UTC
Systematic Review: Preventing Complications and Treating Symptoms of Diabetic Peripheral Neuropathy
26 Aug, 2017 | 16:05h | UTCSystematic Review: Preventing Complications and Treating Symptoms of Diabetic Peripheral Neuropathy – Agency for Healthcare Research and Quality (US) (free)
Review: New treatment options for metastatic renal cell carcinoma
26 Aug, 2017 | 16:02h | UTCNew treatment options for metastatic renal cell carcinoma – ESMO Open (free)
Review: Checkpoint inhibitors in the treatment of urological malignancies
26 Aug, 2017 | 15:58h | UTCCheckpoint inhibitors in the treatment of urological malignancies – ESMO Open (free)
Review: Drug-induced liver injury
26 Aug, 2017 | 15:48h | UTCReview: Drug-induced liver injury: recent advances in diagnosis and risk assessment – Gut (free)
Tranexamic acid reduces risk of death from bleeding after childbirth
24 Aug, 2017 | 23:03h | UTCDrug reduces deaths from bleeding after childbirth – NIHR Signal (free)
Original article: Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial – The Lancet (free) and Editorial: WOMAN: reducing maternal deaths with tranexamic acid (free)
“Tranexamic acid reduces risk of death from bleeding after childbirth by 31% when given within three hours”. (RT @NIHR_DC see Tweet)
Randomized Clinical Trial: Oral Steroid Does Not Reduce Symptoms in Lower Respiratory Tract Infection
24 Aug, 2017 | 20:43h | UTCEffect of Oral Prednisolone on Symptom Duration and Severity in Nonasthmatic Adults With Acute Lower Respiratory Tract Infection: A Randomized Clinical Trial – JAMA (link to abstract – $ for full-text)
Commentaries: Oral Steroid Does Not Reduce Lower Respiratory Tract Infection Symptoms in Nonasthmatic Adults – JAMA Network (free) AND No Benefit for Oral Steroids in Lower Respiratory Tract Infection – Medscape (free registration required) AND Don’t use steroids for chest infections, GPs advised – Pulse (free)
In patients with acute respiratory infection, without evidence of pneumonia or asthma, the addition of corticosteroids did not reduce symptom duration or severity.
Guideline: Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer
22 Aug, 2017 | 20:25h | UTCCommentary: ASCO Guideline on Stage IV NSCLC Therapy Updated – ASCO Post (free)
Review: Cost-Effectiveness of Cardiotoxicity Monitoring
22 Aug, 2017 | 19:01h | UTCRelated Guidelines and Reviews: Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline (free) AND 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines (free) AND Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy (free) AND Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management – CA: A Cancer Journal for Clinicians (free) AND Radiation Associated Cardiac Disease – American College of Cardiology, Latest in Cardiology (free) AND Cardiac Toxicity Of Cancer Chemotherapy – US Cardiology Review (free)
Study: Reductions in Acute Gastroenteritis–Related Hospitalizations and Associated Costs After Implementation of Rotavirus Vaccines
22 Aug, 2017 | 19:06h | UTCCommentary: Rotavirus vaccines continue to reduce diarrhea hospitalizations, medical costs in US kids – Medical News Today (free) AND Study: Rotavirus vaccine cuts healthcare costs in US children – CIDRAP (free)
Cancer treatment: sorting the good news from the hype
22 Aug, 2017 | 14:20h | UTCCancer treatment: sorting the good news from the hype – The Guardian (free)
“The newspapers love a cancer research story, but many are misleading or won’t affect patients for many years. But there is plenty of progress worth reporting”
Study: Dexamethasone vs Placebo on Acute Sore Throat in Adults
22 Aug, 2017 | 15:00h | UTCMultimedia: Author Interview (free) AND JAMA Report Video (free)
Commentaries: Study Examines Effectiveness of Steroid Medication for Sore Throat – The JAMA Network (free) AND Corticosteroids for sore throat: a mixed bag of results – Clinical Advisor (free)
Source: ACP Journal Club ($)
Dexamethasone increased complete symptom resolution at 48 hours (35.4% vs 27.1%), but not at 24 hours. Trade-offs between the benefits and risks of dexamethasone in this situation are uncertain.
Study: Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding
22 Aug, 2017 | 15:19h | UTCGastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial – The Lancet (link to abstract – $ for full-text)
Source: ACP Journal Club
In this study, patients at high risk of both cardiovascular and gastrointestinal events who required concomitant aspirin and NSAID, celecoxib associated with a proton pump inhibitor led to less recurrent gastrointestinal bleeding when compared to naproxen associated with a proton pump inhibitor (5.6% vs 12.3%).
Viewpoint: Considerations on the Off-Label Use of Ketamine as a Treatment for Mood Disorders
22 Aug, 2017 | 14:33h | UTCViewpoint: Considerations on the Off-Label Use of Ketamine as a Treatment for Mood Disorders – JAMA (free)
Systematic Review: Benefits and Harms of Osteoporosis Medications in Patients With Chronic Kidney Disease
22 Aug, 2017 | 15:32h | UTCBenefits and Harms of Osteoporosis Medications in Patients With Chronic Kidney Disease: A Systematic Review and Meta-analysis – Annals of Internal Medicine (link to abstract – $ for full-text)
Commentaries: Benefits and harms of osteoporosis medications unclear for patients with CKD – Medical News Today (free) AND Benefits and harms of osteoporosis medications unclear for patients with CKD – 2 Minute Medicine (free)
Source: ACP Journal Club ($)